Michael Frost_KT Annual Meeting 2019. Photo by Christian Ove Carlsson

Savings on water and energy consumption

As a world-leading supplier of industrial enzymes, and situated in the vicinity of DTU, Novozymes is a natural KT-Consortium member.

“We have a general interest in KT activities. Currently, projects which may contribute to increased sustainability in our processes have extra focus. We are constantly looking for possible new processes able to lower consumption of water, energy, and other resources, while maintaining the high quality of end products,” says Dr. Michael Frost, downstream processing specialist at Novozymes.

“Also, we welcome the ongoing expansion of the Pilot Plant facilities at DTU Chemical Engineering. We see this as an important link between the lab experiments and the industrial scale.”

Michael Frost works in recovery development at Novozymes. In relation to enzyme production, recovery is what happens after microorganisms have produced the relevant enzyme by fermentation. The resulting “soup” is not a commercial product. A series of processes is needed to remove impurities and condense the content of desired enzymes into either a liquid or solid end product.

“The key word here is control. The better we are able to control our processes, the less water and energy will we need to get to the end result. Reduced consumption of raw materials equals better sustainability, and also improves the business case,” Michael Frost explains.

Since obtaining his PhD in chemical engineering at DTU more than four years ago, Michael Frost has worked in Novozymes, but has stayed in touch with DTU through the KT-Consortium.

“I have enjoyed the ongoing contact with my former colleagues. The community around the KT-Consortium is quite remarkable. There is a high degree of openness regarding the science taking part at DTU Chemical Engineering, making it easy for a company like us to see where the possibilities for collaboration lie. Further, I find the group to be alert to topics which are relevant in an industrial context. This applies equally to pharma and biotechnology, the two main fields in the work of the consortium. And last but not least, we just find the faculty members easy to talk to.”